

# About IAVI



Translating science  
into global health impact

IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

## Key program areas

IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we're doing to help solve them.

### ▶ HIV

HIV infects 1.7 million people per year, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

- Advance the next generation of vaccines to prevent HIV infection by pairing sophisticated science with community-rooted research.
- Develop injectable antibodies against HIV that can prevent infection for as long as six months with one dose.
- Partner with Africa to end HIV through ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement with the U.S. Agency for International Development through the U.S. President's Emergency Plan for AIDS Relief.

### ▶ Tuberculosis (TB)

TB disease is the leading cause of death from infectious diseases and leading killer of people living with HIV; TB accounts for more than 1 in 4 antimicrobial resistance deaths annually.

- Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

### ▶ Emerging Infectious Diseases

We need rapid, scalable vaccine technologies for diseases that pose public health and bioterror threats.

- Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, Ebola virus diseases, and COVID-19.

## IAVI's Impact\*



**837,545**

people in Africa linked to treatment and care through IAVI-Africa clinical research center network



**7,360**

participants enrolled in three completed TB vaccine efficacy trials



**3,062**

people in the developing world trained in Good Clinical Practices to international standards for conducting clinical trials



**105**

potent and broad HIV-neutralizing antibodies identified and used in research for vaccine design and other prevention and treatment modalities



**72**

IAVI-sponsored clinical trials of HIV vaccines and antibodies and TB vaccines conducted in 14 countries



**51**

population-based studies conducted by IAVI or partner institutions that have provided data for HIV vaccine and biomedical prevention design and clinical evaluation



**20**

Phase I clinical trials, both of vaccines and antibodies, assisted by IAVI's Product Development Center

\*As of May 2020

Sources available at [iavi.org/fact-sheets-sources](https://iavi.org/fact-sheets-sources)

## ► Neglected Diseases

Nearly 3 million people, primarily in LMICs, suffer snakebite envenoming annually; antivenom is costly, toxic, and of inconsistent quality.

- Develop cheaper, safer, more potent antibody products that target venoms of medically important snakes in India and Africa.

## ► Product Development Center

Most promising candidates never progress past the discovery phase to become licensed products.

- Engage a global team of experts to bridge the “valley of death” in vaccine and antibody development so today’s laboratory concepts become tomorrow’s public health solutions.

## IAVI Fast Facts

- More than 20 years of breakthrough TB and HIV vaccine research
- 215 employees
- Headquarters in New York City
- Staff in 7 countries (India, Kenya, Netherlands, South Africa, Uganda, U.K., U.S.)
- Labs in La Jolla, California; Brooklyn, New York; London, U.K.; and Faridabad, India
- 2019 revenue: \$88.8M
- Revenue breakdown: 58% governments and multilaterals; 39% foundations and individuals; 3% investments and other sources
- 501(c)(3) nonprofit organization
- Charity Navigator 4-star rating; GuideStar Seal of Approval 2019 Platinum rating

IAVI Pipeline: 2020–2022												
Candidate (Protocol)	2020				2021				2022			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Candidates designed to induce neutralizing and broadly neutralizing antibodies against HIV	BG505 GT1.1 gp140, adjuvanted (IAVI C101) Phase I											
	eOD-GT8 60mer, adjuvanted (IAVI G001) Phase I											
	BG505 SOSIP gp140, adjuvanted (IAVI W001) Phase I											
Passive immunization against HIV via bnAbs	Enhanced bnAbs for HIV prevention Preclinical Phase I/II											
	bnAbs PGT121, PGDM1400, and VRC07-523LS (T002, T003) Phase I T002 Phase I / IIa T003											
	bnAbs 3BNC117 and 10-1074 (IAVI C100) Phase I / II LS-J molecules											
Replicating viral vector-based vaccine candidates	rVSVΔG-Env.BG505 (HIV), rVSV Ebola-Sudan Preclinical											
	rVSV-Marburg Preclinical Phase I											
	rVSV-Lassa Preclinical Phase I											
Antibodies for treatment of COVID-19	rVSV-SARS-CoV-2 (V590-001) Preclinical Phase I Phase III											
	Antibody 1 (CC6.35); Antibody 2 Preclinical Phase I Phase II/III											
Tuberculosis vaccine candidates	MTBVAC (A-050) Phase Ib/IIa											
	H56/IC31® (A-055 POR) Phase II											

IAVI gratefully acknowledges the generous support provided by the following major donors:



Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | The Buimerc Group | Broadway Cares/Equity Fights AIDS | Cancer Research UK | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of September 2020



[iavi.org](http://iavi.org)  
[info@iavi.org](mailto:info@iavi.org)

Go to [iavi.org/subscribe](http://iavi.org/subscribe) to receive our updates  
Find us on Twitter [@iavi](https://twitter.com/iavi)